The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
STING activation in cancer immunotherapy
Open accessAbstract
Cancer immunotherapy modulates and leverages the host immune system to treat cancer. The past decade has witnessed historical advancement of cancer immunotherapy. A myriad of approaches have been explored to elicit or augment anticancer innate immunity and/or adaptive immunity. Recently, activation of stimulator of interferon (IFN) genes (STING), an intracellular receptor residing in the endoplasmic reticulum, has shown great potential to enhance antitumor immunity through the induction of a variety of pro-inflammatory cytokines and chemokines, including type I IFNs. A number of natural and synthetic STING agonists have been discovered or developed, and tested in preclinical models and in the clinic for the immunotherapy of diseases such as cancer and infectious diseases. Cyclic dinucleotides (CDNs), such as cyclic dimeric guanosine monophosphate (c-di-GMP), cyclic dimeric adenosine monophosphate (c-di-AMP), and cyclic GMP-AMP (cGAMP), are a class of STING agonists that can elicit immune responses. However, natural CDNs are hydrophilic small molecules with negative charges and are susceptible to enzymatic degradation, leading to low bioavailability in target tissues yet unwanted toxicities and narrow therapeutic windows. Drug delivery systems, coupled with nucleic acid chemistry, have been exploited to address these challenges. Here, we will discuss the underlying immunological mechanisms and approaches to STING activation, with a focus on the delivery of STING agonists, for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576
Biodegradable polymeric nanoparticles as drug delivery devices
Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00339-4 · Cited by 3,549
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759 · cited 11×
“As discussed above, small molecule STING agonists as well as cytosolic DNA species can stimulate the STING signaling pathway to promote antigen presentation and T cell priming for tumor eradication [51-54].”
BackgroundInfluentialDeng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
Controlled drug delivery vehicles for cancer treatment and their performance
Senapati, S., Mahanta, A. K., Kumar, S., & Maiti, P. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-017-0004-3 · Cited by 2,167
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834
CGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING.
Ablasser, A., Goldeck, M., Cavlar, T., Deimling, T., Witte, G., Röhl, I., Hopfner, K.-P., Ludwig, J., & Hornung, V. (2013) · Nature · doi:10.1038/nature12306 · Cited by 1,695
STING is a direct innate immune sensor of cyclic di-GMP
Burdette, D. L., Monroe, K. M., Sotelo-Troha, K., Iwig, J. S., Eckert, B., Hyodo, M., Hayakawa, Y., & Vance, R. E. (2011) · Nature · doi:10.1038/nature10429 · Cited by 1,570
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
The Adaptor Protein MITA Links Virus-Sensing Receptors to IRF3 Transcription Factor Activation
Zhong, B., Yang, Y., Li, S., Wang, Y.-Y., Li, Y., Diao, F., Lei, C., He, X., Zhang, L., Tien, P., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.09.003 · Cited by 1,519
Activated STING in a Vascular and Pulmonary Syndrome
Liu, Y., Jesus, A. A., Marrero, B., Yang, D., Ramsey, S. E., Montealegre Sanchez, G. A., Tenbrock, K., Wittkowski, H., Jones, O. Y., Kuehn, H. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312625 · Cited by 1,412
STING: infection, inflammation and cancer.
Barber, G. N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3921 · Cited by 1,313
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
The convergence of synthetic organic and polymer chemistries
Hawker, C. J., & Wooley, K. L. (2005) · Science · doi:10.1126/science.1109778 · Cited by 1,298
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216
Immunogenic and tolerogenic cell death
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176
Immunomodulatory functions of type I interferons
González-Navajas, J. M., Lee, J., David, M., & Raz, E. (2012) · Nature Reviews Immunology · doi:10.1038/nri3133 · Cited by 1,011
The cGAS-cGAMP-STING Pathway of Cytosolic DNA Sensing and Signaling
Cai, X., Chiu, Y.-H., & Chen, Z. J. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.03.040 · Cited by 988
Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer
Chen, Q., Boire, A., Jin, X., Valiente, M., Er, E. E., Lopez-Soto, A., S. Jacob, L., Patwa, R., Shah, H., Xu, K., et al. (2016) · Nature · doi:10.1038/nature18268 · Cited by 969
Design of amidobenzimidazole STING receptor agonists with systemic activity
Ramanjulu, J. M., Pesiridis, G. S., Yang, J., Concha, N., Singhaus, R., Zhang, S.-Y., Tran, J.-L., Moore, P., Lehmann, S., Eberl, H. C., et al. (2018) · Nature · doi:10.1038/s41586-018-0705-y · Cited by 912
A STING-activating nanovaccine for cancer immunotherapy
Luo, M., Wang, H., Wang, Z., Cai, H., Lu, Z., Li, Y., Du, M., Huang, G., Wang, C., Chen, X., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.52 · Cited by 900
Burnette, B. C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N. N., Weichselbaum, R. R., Fu, Y.-X., & Auh, S. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2820 · Cited by 878
Woodward, J. J., Iavarone, A. T., & Portnoy, D. A. (2010) · Science · doi:10.1126/science.1189801 · Cited by 810
Diner, E. J., Burdette, D. L., Wilson, S. C., Monroe, K. M., Kellenberger, C. A., Hyodo, M., Hayakawa, Y., Hammond, M. C., & Vance, R. E. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.05.009 · Cited by 767
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Fu, J., Kanne, D. B., Leong, M., Glickman, L. H., McWhirter, S. M., Lemmens, E., Mechette, K., Leong, J. J., Lauer, P., Liu, W., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4306 · Cited by 720
Integrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704
Konno, H., Konno, K., & Barber, G. N. (2013) · Cell · doi:10.1016/j.cell.2013.09.049 · Cited by 687
Shae, D., Becker, K. W., Christov, P., Yun, D. S., Lytton-Jean, A. K. R., Sevimli, S., Ascano, M., Kelley, M., Johnson, D. B., Balko, J. M., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0342-5 · Cited by 668
Longhi, M. P., Trumpfheller, C., Idoyaga, J., Caskey, M., Matos, I., Kluger, C., Salazar, A. M., Colonna, M., & Steinman, R. M. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090247 · Cited by 663
Xia, T., Konno, H., Ahn, J., & Barber, G. N. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.029 · Cited by 589
PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.054 · Cited by 572 · cited 1×
“These results shed lights on the mechanisms of the therapeutic effects of PARP inhibitors in BRCA1-deficient tumors [97].”
BackgroundcGAS is essential for the antitumor effect of immune checkpoint blockade
Wang, H., Hu, S., Chen, X., Shi, H., Chen, C., Sun, L., & Chen, Z. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621363114 · Cited by 563
Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs
Li, L., Yin, Q., Kuss, P., Maliga, Z., Millán, J. L., Wu, H., & Mitchison, T. J. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1661 · Cited by 533
Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
Kitajima, S., Ivanova, E., Guo, S., Yoshida, R., Campisi, M., Sundararaman, S. K., Tange, S., Mitsuishi, Y., Thai, T. C., Masuda, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0689 · Cited by 526
STING manifests self DNA-dependent inflammatory disease
Ahn, J., Gutman, D., Saijo, S., & Barber, G. N. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215006109 · Cited by 509
Type I Interferon in Chronic Virus Infection and Cancer
Snell, L. M., McGaha, T. L., & Brooks, D. G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.05.005 · Cited by 500
The host STING pathway at the interface of cancer and immunity
Corrales, L., McWhirter, S. M., Dubensky, T. W., & Gajewski, T. F. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86892 · Cited by 487
Parkes, E. E., Walker, S. M., Taggart, L. E., McCabe, N., Knight, L. A., Wilkinson, R., McCloskey, K. D., Buckley, N. E., Savage, K. I., Salto-Tellez, M., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw199 · Cited by 462
Material design for lymph node drug delivery
Schudel, A., Francis, D. M., & Thomas, S. N. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0110-7 · Cited by 460
Jin, L., Waterman, P. M., Jonscher, K. R., Short, C. M., Reisdorph, N. A., & Cambier, J. C. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00640-08 · Cited by 450
RIG-I in RNA virus recognition
Kell, A. M., & Gale, M. (2015) · Virology · doi:10.1016/j.virol.2015.02.017 · Cited by 428
Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis
Xia, T., Konno, H., & Barber, G. N. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1404 · Cited by 383
Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants
Hanson, M. C., Crespo, M. P., Abraham, W., Moynihan, K. D., Szeto, G. L., Chen, S. H., Melo, M. B., Mueller, S., & Irvine, D. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79915 · Cited by 381
STING-dependent cytosolic DNA sensing pathways
Barber, G. N. (2014) · Trends in Immunology · doi:10.1016/j.it.2013.10.010 · Cited by 336
Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors
Smith, T. T., Moffett, H. F., Stephan, S. B., Opel, C. F., Dumigan, A. G., Jiang, X., Pillarisetty, V. G., Pillai, S. P. S., Wittrup, K. D., & Stephan, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87624 · Cited by 336
Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells
Tang, C.-H. A., Zundell, J. A., Ranatunga, S., Lin, C., Nefedova, Y., Del Valle, J. R., & Hu, C.-C. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1885 · Cited by 319
Kitai, Y., Kawasaki, T., Sueyoshi, T., Kobiyama, K., Ishii, K. J., Zou, J., Akira, S., Matsuda, T., & Kawai, T. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601694 · Cited by 318
Delivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
Self-citationSTING Recognition of Cytoplasmic DNA Instigates Cellular Defense
Abe, T., Harashima, A., Xia, T., Konno, H., Konno, K., Morales, A., Ahn, J., Gutman, D., & Barber, G. N. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.039 · Cited by 299
Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
Wang, C., Ye, Y., Hu, Q., Bellotti, A., & Gu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201606036 · Cited by 286
Nanomaterials for cancer immunotherapy
Song, W., Musetti, S. N., & Huang, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.017 · Cited by 281
Gene therapy progress and prospects: synthetic polymer-based systems
Schaffert, D., & Wagner, E. (2008) · Gene Therapy · doi:10.1038/gt.2008.105 · Cited by 277
Cheng, N., Watkins-Schulz, R., Junkins, R. D., David, C. N., Johnson, B. M., Montgomery, S. A., Peine, K. J., Darr, D. B., Yuan, H., McKinnon, K. P., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120638 · Cited by 260
Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy
Koshy, S. T., Cheung, A. S., Gu, L., Graveline, A. R., & Mooney, D. J. (2017) · Advanced Biosystems · doi:10.1002/adbi.201600013 · Cited by 256
STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer
Chandra, D., Quispe-Tintaya, W., Jahangir, A., Asafu-Adjei, D., Ramos, I., Sintim, H. O., Zhou, J., Hayakawa, Y., Karaolis, D. K. R., & Gravekamp, C. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0123 · Cited by 231
Cyclic Dinucleotides and the Innate Immune Response
Danilchanka, O., & Mekalanos, J. J. (2013) · Cell · doi:10.1016/j.cell.2013.08.014 · Cited by 228
Bacterial c-di-GMP Is an Immunostimulatory Molecule
Karaolis, D. K. R., Means, T. K., Yang, D., Takahashi, M., Yoshimura, T., Muraille, E., Philpott, D., Schroeder, J. T., Hyodo, M., Hayakawa, Y., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2171 · Cited by 222
STING-mediated intestinal barrier dysfunction contributes to lethal sepsis
Hu, Q., Ren, H., Li, G., Wang, D., Zhou, Q., Wu, J., Zheng, J., Huang, J., Slade, D. A., Wu, X., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.055 · Cited by 221
Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy
Wilson, D. R., Sen, R., Sunshine, J. C., Pardoll, D. M., Green, J. J., & Kim, Y. J. (2018) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2017.10.013 · Cited by 220
cGAS–STING and Cancer: Dichotomous Roles in Tumor Immunity and Development
Ng, K. W., Marshall, E. A., Bell, J. C., & Lam, W. L. (2018) · Trends in Immunology · doi:10.1016/j.it.2017.07.013 · Cited by 218
STING-Mediated DNA Sensing Promotes Antitumor and Autoimmune Responses to Dying Cells
Klarquist, J., Hennies, C. M., Lehn, M. A., Reboulet, R. A., Feau, S., & Janssen, E. M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401869 · Cited by 211
Ohkuri, T., Kosaka, A., Ishibashi, K., Kumai, T., Hirata, Y., Ohara, K., Nagato, T., Oikawa, K., Aoki, N., Harabuchi, Y., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1975-1 · Cited by 201
Nakamura, T., Miyabe, H., Hyodo, M., Sato, Y., Hayakawa, Y., & Harashima, H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.026 · Cited by 198
STINGel: Controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy
Leach, D. G., Dharmaraj, N., Piotrowski, S. L., Lopez-Silva, T. L., Lei, Y. L., Sikora, A. G., Young, S., & Hartgerink, J. D. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.01.035 · Cited by 196
Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells
Ahn, J., Xia, T., Rabasa Capote, A., Betancourt, D., & Barber, G. N. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.027 · Cited by 189
Ager, C. R., Reilley, M. J., Nicholas, C., Bartkowiak, T., Jaiswal, A. R., & Curran, M. A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0049 · Cited by 180
Dubensky, T. W., Kanne, D. B., & Leong, M. L. (2013) · Therapeutic Advances in Vaccines · doi:10.1177/2051013613501988 · Cited by 175
The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axis
Roberts, Z. J., Goutagny, N., Perera, P.-Y., Kato, H., Kumar, H., Kawai, T., Akira, S., Savan, R., van Echo, D., Fitzgerald, K. A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061845 · Cited by 169
A new adjuvant delivery system ‘cyclic di-GMP/YSK05 liposome’ for cancer immunotherapy
Miyabe, H., Hyodo, M., Nakamura, T., Sato, Y., Hayakawa, Y., & Harashima, H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.004 · Cited by 163
Foote, J. B., Kok, M., Leatherman, J. M., Armstrong, T. D., Marcinkowski, B. C., Ojalvo, L. S., Kanne, D. B., Jaffee, E. M., Dubensky, T. W., & Emens, L. A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0284 · Cited by 160
de Queiroz, N. M. G. P., Xia, T., Konno, H., & Barber, G. N. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0504 · Cited by 149
Junkins, R. D., Gallovic, M. D., Johnson, B. M., Collier, M. A., Watkins-Schulz, R., Cheng, N., David, C. N., McGee, C. E., Sempowski, G. D., Shterev, I. D., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.030 · Cited by 147
Synthetic nanovaccines for immunotherapy
Luo, M., Samandi, L. Z., Wang, Z., Chen, Z. J., & Gao, J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.033 · Cited by 129
Modulation of T‐cell function by type I interferon
Tough, D. F. (2012) · Immunology and Cell Biology · doi:10.1038/icb.2012.7 · Cited by 123
Roles of the cGAS-STING Pathway in Cancer Immunosurveillance and Immunotherapy
Yum, S., Li, M., Frankel, A. E., & Chen, Z. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055636 · Cited by 110
Karaolis, D. K. R., Cheng, K., Lipsky, M., Elnabawi, A., Catalano, J. G., Hyodo, M., Hayakawa, Y., & Raufman, J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.093 · Cited by 104
Luo, M., Liu, Z., Zhang, X., Han, C., Samandi, L. Z., Dong, C., Sumer, B. D., Lea, J. S., Fu, Y., & Gao, J. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.02.036 · Cited by 98
An, M., Yu, C., Xi, J., Reyes, J. D., Mao, G., Wei, W., & Liu, H. (2018) · Nanoscale · doi:10.1039/c8nr01376d · Cited by 97
Watkins-Schulz, R., Tiet, P., Gallovic, M. D., Junkins, R. D., Batty, C. J., Bachelder, E. M., Ainslie, K. M., & Ting, J. P. ‐. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.03.011 · Cited by 93
The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties
Ebensen, T., Schulze, K., Riese, P., Link, C., Morr, M., & Guzmán, C. A. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.10.033 · Cited by 84
c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection
Ogunniyi, A. D., Paton, J. C., Kirby, A. C., McCullers, J. A., Cook, J., Hyodo, M., Hayakawa, Y., & Karaolis, D. K. R. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.06.099 · Cited by 80
Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists
Collier, M. A., Junkins, R. D., Gallovic, M. D., Johnson, B. M., Johnson, M. M., Macintyre, A. N., Sempowski, G. D., Bachelder, E. M., Ting, J. P.-Y., & Ainslie, K. M. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00579 · Cited by 79
Immunomodulatory Actions of Xanthenone Anticancer Agents
Baguley, B. C., & Ching, L. (1997) · BioDrugs · doi:10.2165/00063030-199708020-00005 · Cited by 60
cGAS-STING Activation in the Tumor Microenvironment and Its Role in Cancer Immunity
Pépin, G., & Gantier, M. P. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-5987-2_8 · Cited by 54
Shu, H., & Wang, Y. (2014) · Immunity · doi:10.1016/j.immuni.2014.12.002 · Cited by 49
Lee, E. H., Jang, H.-E., Kang, Y. Y., Kim, J., Ahn, J., & Mok, H. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.10.025 · Cited by 49
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S., Fuertes, M. B., Corrales, L. P., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2014.12.015 · Cited by 39
The emerging role of STING-dependent signaling on cell death
Sun, F., Liu, Z., Yang, Z., Liu, S., & Guan, W. (2019) · Immunologic Research · doi:10.1007/s12026-019-09073-z · Cited by 33
Tumor cGAMP Awakens the Natural Killers
Sundararaman, S. K., & Barbie, D. A. (2018) · Immunity · doi:10.1016/j.immuni.2018.10.001 · Cited by 26
Cited by
Translational Applications of Hydrogels
Correa, S., Grosskopf, A. K., Lopez Hernandez, H., Chan, D., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,143
Exploring the next generation of antibody–drug conjugates
Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
Garland, K. M., Sheehy, T. L., & Wilson, J. T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00750 · Cited by 357
Prolonged activation of innate immune pathways by a polyvalent STING agonist
Li, S., Luo, M., Wang, Z., Feng, Q., Wilhelm, J., Wang, X., Li, W., Wang, J., Cholka, A., Fu, Y.-X., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00675-9 · Cited by 317
Self-citationCytoplasmic DNA: sources, sensing, and role in aging and disease
Miller, K. N., Victorelli, S. G., Salmonowicz, H., Dasgupta, N., Liu, T., Passos, J. F., & Adams, P. D. (2021) · Cell · doi:10.1016/j.cell.2021.09.034 · Cited by 288
Metadata
- Authors
- Su, T., Zhang, Y., Valerie, K., Wang, X.-Y., Lin, S., & Zhu, G.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2019
- Volume
- 9
- Issue
- 25
- Pages
- 7759-7771
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2982520686
- Cited by
- 256
- References
- 93
- FWCI
- 9.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.